References
- Goldie J H, Coldman A J, Gudauskas G A. Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
- Coldman A J, Goldie J H. A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math Bio Sci 1983; 65: 291–307
- Goldie J H, Coldman A J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44: 3643–3653
- Goldie J H, Goldman A J. A model for tumor response to chemotherapy: An intergration of the stem cell and somatic mutation hypothesis. Cancer Invest 1985; 3: 553–564
- Goldie J H, Coldman A J. Application of theoretical models to chemotherapy protocol design. Cancer Treat Rep 1986; 70: 127–131
- Liepman M K, Wheeler R H, Zuckerman K S, et al. Combination chemotherapy of refractory lymphoma with cisplatinum, dichlorodiamineplatinum, vinblastine and bleomycin. Cancer 1982; 50: 2736–2739
- Berard C W, Gallo R C, Jaffe E S, et al. Current concepts of leukemia and lymphoma: etiology, pathogenesis and therapy. Ann Intern Med 1976; 85: 351–336
- Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457–481
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
- Dixon D O, McLaughlin P, Hagemeister F B, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 1987; 5: 1670–1672
- Documenta Geigy. Scientific Tables, 7th ed., K Diem, C. Lentner. Geigy Pharmaceuticals, Ardsley, NY 1971, reprinted
- Jones S E, Grozea P N, Metz E N, et al. Superiority of adriamycin containing combination chemotherapy in the treatment of diffuse lymphoma. A Southwest Oncology Group Study. Cancer 1979; 43: 417–425
- Coltman C A, Jr, Dahlberg S, Jones S E, et al. CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: A twelve year Southwest Oncology Group follow up. Third International Conference on Malignant Lymphoma. 1987, abstr, 53
- Armitage J O, Weisenburger D D, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma—rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4: 160–164
- Armitage J O, Dick F R, Corder M P, et al. Predicting therapeutic outcome in patients with diffuse histocytic lymphoma treated with cyclosphosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1982; 50: 1695–1702
- Heinz R, Neumann E, Aiginger P, et al. CHOP—firstline treatment in NHL with unfavorable prognosis—evaluation of therapeutic response and factors influencing prognosis. Blut 1985; 50: 768–777
- Corder M P, Clamon G H. Salvage therapy of aggressive non-Hodgkin's lymphoma with a combination of vinblastine, bleomycin and cisplatin. Cancer 1984; 54: 202–206
- Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treatment Rep 1986; 70: 163–168